Patients receiving treatment with hydroxychloroquine (HCQ) for rheumatological conditions are not protected from SARS-CoV-2 infection, according to the results of a retrospective study of data from a US Veterans Health Administration database. During the study period (March–June 2020), the incidence of active infections did not differ between patients who received HCQ (31 of 10,703 (0.3%)) and those who did not (78 of 21,406 (0.4%)). The two groups also did not differ in rate of hospital admission, requirement of intensive care and mortality associated with SARS-CoV-2 infection.
References
Original article
Gentry, C. A. et al. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheum. https://doi.org/10.1016/S2665-9913(20)30305-2 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. HCQ use not protective against SARS-CoV-2. Nat Rev Rheumatol 16, 666 (2020). https://doi.org/10.1038/s41584-020-00529-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-00529-3
